Clinical Trial

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-04.
Trial Details
NCT Number NCT06816914
Lead Sponsor Taichung Veterans General Hospital
Collaborators: National Cheng-Kung University Hospital, Chang Gung Memorial Hospital, Taipei Veterans General Hospital, Taiwan, National Taiwan University Hospital, China Medical University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Tri-Service General Hospital (TSGH)
Conditions Resectable Pancreatic Adenocarcinoma
Enrollment 84 participants
Start Date 2025-03-05
Primary Completion 2027-02-05 (estimated)
Study Completion 2028-02-05 (estimated)
Updated on ClinicalTrials.gov 2025-02-20